<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102660">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095860</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-111</org_study_id>
    <nct_id>NCT02095860</nct_id>
  </id_info>
  <brief_title>Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325</brief_title>
  <official_title>An Open-label, Randomized, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Daclatasvir, Asunaprevir, and BMS-791325 Following Administration of a Single Fixed Dose Combination of DCV 3DAA FDC in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of a high fat meal and light meal on the
      blood levels of Daclatasvir, Asunaprevir and BMS-791325 after administration of the 3 drugs
      as a fixed-dose combination in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IND Number: 100,932/79,599/101,943

      Primary Purpose:

      Other: Phase 1 clinical pharmacology bioavailability study to assess food effect
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of DCV, ASV and BMS-791325</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of DCV, ASV and BMS-791325</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] for DCV, ASV and BMS-791325</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) for DCV, ASV and BMS-791325</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma half life (T-HALF) for DCV, ASV and BMS-791325</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-T) for BMS-794712</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(INF) for BMS-794712</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for BMS-794712</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for BMS-794712</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALF for BMS-794712</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by incidence of adverse event (AEs), serious AEs (SAEs) and AEs leading to discontinuation</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by abnormalities in vital sign measurements</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by findings on electrocardiograms (ECG) measurements and physical examinations</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by marked abnormalities in clinical laboratory test results</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment A: DCV 3DAA FDC fasted state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCV 3 Direct Acting Antiviral (DAA) Fixed Dose Combination (FDC) tablet by mouth once on specified days in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: DCV 3DAA FDC with high-fat meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCV 3DAA FDC tablet by mouth once on specified days with high-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: DCV 3DAA FDC with light meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCV 3DAA FDC tablet by mouth once on specified days with light meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCV 3DAA FDC</intervention_name>
    <description>Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325</description>
    <arm_group_label>Treatment A: DCV 3DAA FDC fasted state</arm_group_label>
    <arm_group_label>Treatment B: DCV 3DAA FDC with high-fat meal</arm_group_label>
    <arm_group_label>Treatment C: DCV 3DAA FDC with light meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy male and female subjects ages 18 to 49 years, inclusive.

          -  Women of childbearing potential must be using an acceptable method of contraception
             for at least 4 weeks prior to study drug administration.

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease

          -  Any gastrointestinal surgery that could impact upon the absorption of study drug,
             including cholecystectomy

          -  History of biliary disorders, including Gilbert's syndrome or Dubin-Johnson disease

          -  Use of tobacco-containing or nicotine-containing products

          -  Any of the following on 12-lead electrocardiogram (ECG) prior to study drug
             administration, confirmed by repeat:

               -  PR ≥210 msec

               -  QRS ≥120 msec

               -  QT ≥500 msec

               -  QTcF ≥450 msec

          -  Any of the following laboratory results outside of the ranges specified below prior
             to study drug administration, confirmed by repeat:

               -  Alanine aminotransferase (ALT) &gt;Upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST) &gt;ULN

               -  Total bilirubin (TBILI) &gt;ULN

               -  Creatinine &gt;ULN
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Healthcare Discoveries, Llc D/B/A Icon Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuel Denoia, Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
